Pre-diabetes Clinical Trial
— STOP-GOOfficial title:
A Multicenter, Randomized, Controlled Trial to Prevent Diabetes With Short-term Insulin Glargine Treatment or Lifestyle Intervention
- Pre-diabetes is a significant risk factor for the development of type 2 diabetes, as
well as macrovascular and microvascular complication.
- Previous studies show that 50% or more loss in islet B-cell function even in
Pre-diabetes phase. The early insulin therapy in pre-diabetes may be a strategy in
preventing metabolic disorders and cardiovascular disease.
- The objective of this study is to find if an initial insulin glargine intervention in
pre-diabetes (IGT and /or IFG) could be a strategy in preventing type 2 Diabetes.
- Pre-diabetes subjects will receive a insulin glargine therapy with a dosage adjusted to
get FBG ≤ 5.3mmol / L as the goal. Insulin glargine treatment will be maintained for
three months thereafter to find if it can prevent diabetes.
Status | Recruiting |
Enrollment | 2420 |
Est. completion date | December 2013 |
Est. primary completion date | October 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 25 Years to 65 Years |
Eligibility |
Inclusion Criteria: 1. All participants are voluntary and write informed consent 2 weeks before enrollment. 2. Fasting Blood Glucose between >= 5.6mmol/L and <7.0mmol/L, and HbA1c between >= 5.7% and <6.5%. 3. Both male and female aged between >= 25 and = 65 years. 4. Participants have the ability to use self-monitoring devices to measure their blood glucose level and practice self-insulin injection. 5. Have the ability and willingness to complete the study logs and questionnaires. 6. Pregnancy test of all child-bearing age women should be negative, and they agree to adopt contraceptive measures in the study process. Exclusion Criteria: 1. With previous diagnosis of diabetes or application of hypoglycemic drugs. 2. Preliminary screen for fasting plasma glucose lever =7.0mmol/L or <5.6mmol/L. 3. Preliminary screen for HbA1c result HbA1c<5.7% or = 6.5%. 4. Receiving cancer treatment in the past 5 years. 5. Preliminary diagnostic anti-HIV test result positive, with no serological testing. 6. People with active tuberculosis. 7. Persons hospitalized for heart disease and received the treatment measures (such as coronary artery bypass graft CABG, percutaneous transluminal coronary angioplasty PTCA), while not include diagnostic measures (such as percutaneous coronary angiography) in the past 6 months. 8. Cardiac function evaluated by New York Heart Association criteria (NYHA) = 3 cardiac function level 9. Uncontrolled high blood pressure - systolic blood pressure > 180mmHg or diastolic blood pressure > 105mmHg after treatment. 10. Stroke or transient ischemic attack episode in the past 6 months. 11. With chronic hepatitis or active liver disease, or serum AST or ALT 2.5 times the upper limit of normal. 12. Male serum creatinine = 124µmol/L (1.4mg/dL); Female serum creatinine = 115µmol/L (1.3mg/dL). 13. Systemic glucocorticoids applications, but other than local, eye, and inhalation applications. 14. Anemia: male hematocrit <36.0%; female <33.0%. 15. Other chronic diseases which may lead to the expected life less than 6 years or conditions that may affect life expectancy. 16. Mental disorder history. 17. Alcohol consumption (average 50g or more high spirits drink or 100g or more low spirits drink) or drug abuse. 18. Unable or unwilling to sign informed consent. 19. Cannot communicate or contact with the clinical staff. 20. Unwilling to receive insulin injection therapy or conduct self-monitoring of blood glucose. 21. Unsatisfied control of thyroid disease - subjects who are suffering thyroid disease or receiving anti-thyroid drugs or thyroid hormone treatment, show the sensitive TSH abnormalities (except for patients with low TSH who have the history of thyroid tumor or thyroid cancer receiving the inhibitor treatment). 22. Any other factors that may affect compliance or adverse events reported during the research program. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
China | Beijing Tongren Hospital | Beijing |
Lead Sponsor | Collaborator |
---|---|
Beijing Tongren Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | HbA1c >= 6.5% | Two years | No | |
Secondary | FPG >= 7.0 for two times in a month. | Two years | No | |
Secondary | HbA1c >= 7.0% | Two years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Enrolling by invitation |
NCT05367024 -
Broccoli Effect on Glycated Haemoglobin (HbA1c)
|
N/A | |
Withdrawn |
NCT02400450 -
Designer Functional Foods on Parameters of Metabolic and Vascular in Prediabetes
|
N/A | |
Completed |
NCT02933424 -
Project Plant Protein: the P3 Study in Humans
|
N/A | |
Completed |
NCT02656212 -
Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin (Part 2)
|
Phase 1 | |
Completed |
NCT02330276 -
Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin
|
Phase 1 | |
Completed |
NCT01488279 -
Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy
|
N/A | |
Completed |
NCT00831129 -
A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs
|
Phase 2/Phase 3 | |
Completed |
NCT00536250 -
Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth
|
N/A | |
Recruiting |
NCT05563090 -
Investigating the Syndrome Differentiation of Diabetic and Pre-diabetic Using Digitalized TCM Diagnostic Tools
|
||
Active, not recruiting |
NCT04991142 -
Models of Nutrition From Continuous Glucose Monitors
|
||
Completed |
NCT02759055 -
Pre-Diabetes Cardiovascular (CV) Care (Pre-Diabetes Wizard)
|
N/A | |
Completed |
NCT00775684 -
Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass
|
N/A | |
Completed |
NCT03695913 -
Continuous Glucose Monitoring (CGM) With a Low Carbohydrate Diet to Reduce Weight in Patients With Pre-Diabetes
|
N/A | |
Completed |
NCT04051008 -
CTSI Pilot: Improving Adherence to Diabetic Diet
|
N/A | |
Recruiting |
NCT04897945 -
A Shared Decision Making Intervention for Diabetes Prevention in Women With a History of Gestational Diabetes Mellitus
|
N/A | |
Not yet recruiting |
NCT04442451 -
Mechanisms of Fatigability With Diabetes
|
N/A | |
Not yet recruiting |
NCT05925933 -
High Protein Diet on Transcriptomic, Metabolomics, Hepatic and Pancreatic Fat Anatomy and Physiology in Asian Indians With Pre-diabetes
|
N/A | |
Active, not recruiting |
NCT05654051 -
The SLIM LIVER Study
|
Phase 2 | |
Completed |
NCT02919397 -
Motivational Instant Messaging and E-diabetes Prevention Programme for High Risk of Type 2 Diabetes
|
N/A |